A3P Biomedical
Martin Steinberg is an accomplished executive with extensive experience in the biotechnology and investment sectors. Currently, Steinberg serves as the Chairman of the Board at A3P Biomedical, focusing on enhancing prostate cancer diagnostics and treatment through the company's lead product, Stockholm3. Additionally, Steinberg co-founded OMSHAB and has held key leadership roles, including Head of Business Development at Digital Vision and Investment Manager at Litorina Kapital. Previous experience includes serving as Director at DeLaval and Manager/Project Leader at Arthur D. Little. Steinberg holds an MBA in Business and Economics from the Stockholm School of Economics.
This person is not in any teams
This person is not in any offices
A3P Biomedical
1 followers
A3P Biomedical provides prostate cancer diagnosis and treatment. They specialize in advanced prostate cancer diagnostics. Their main product, Stockholm3, is a clinically and commercially validated blood test for the early detection of aggressive prostate cancer. The test combines protein markers, genetic markers, and clinical data in a proprietaryalgorithm for the purpose of detecting aggressive prostate cancer at an early stage.